𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Radioisotopic Localization of90Yttrium–Ibritumomab Tiuxetan in Patients with CD20+ Non-Hodgkin’s Lymphoma

✍ Scribed by S. A. Jacobs; A. M. Harrison; S. H. Swerdlow; K. A. Foon; N. Avril; N. Vidnovic; J. Joyce; N. DeMonaco; K. S. McCarty

Book ID
106571398
Publisher
Springer-Verlag
Year
2008
Tongue
English
Weight
589 KB
Volume
11
Category
Article
ISSN
1536-1632

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term responses in patients with rec
Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan
✍ Thomas E. Witzig; Arturo Molina; Leo I. Gordon; Christos Emmanouilides; Russell 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB

## Abstract ## BACKGROUND. Radioimmunotherapy with radiolabeled monoclonal antibodies to CD20 produces a high response rate in patients with recurring non‐Hodgkin lymphoma (NHL), but the durability of those remissions is not well defined. ## METHODS. Data on patients with recurring NHL treated w

A phase 2 trial of fludarabine and mitox
A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma
✍ Pier Luigi Zinzani; Monica Tani; Stefano Fanti; Vittorio Stefoni; Gerardo Musura 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB 👁 1 views

## Abstract ## BACKGROUND A prospective, single‐arm, open‐label, nonrandomized Phase 2 study of combined fludarabine and mitoxantrone (FM) plus radioimmunotherapy was conducted to evaluate efficacy and safety in patients with untreated, indolent, nonfollicular non‐Hodgkin lymphoma (NHL). ## METHO